Aduhelm (aducanumab-avwa) was granted accelerated approval by the FDA in June 2021 despite misgivings from the agency’s Peripheral and Central Nervous System Drugs Advisory Committee.
Biogen Pulls Plug on Controversial Alzheimer Disease Drug Aduhelm
Posted on by admin
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
1 min read
+ There are no comments
Add yours